Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019

Влияние колхицина по сравнению со стандартной терапией на сердечные и воспалительные биомаркеры и клинические исходы у пациентов, госпитализированных с коронавирусной инфекцией 2019 года
Christodoulos Stefanadis, Konstantinos P Tsioufis, John A. Goudevenos, Periklis A. Davlouros, Roxana Mehran, Konstantinos Syrigos, Demosthenes G. Katritsis, George Dangas, Vlasios N. Pyrgakis, Giulio Giuseppe Stefanini, Lampros K. Michalis, Bernhard Reimers, Georgios Sianos, Symeon Metallidis, Spyridon G. Deftereos, Antonis S. Manolis, Efstathios K. Iliodromitis, Filippos K. Triposkiadis, Ilias N. Migdalis, Gerasimos Siasos, MICHAEL W. CLEMAN, Katerina Κ. Naka, Luis Martínez‐Dolz, Dimitrios K. Alexopoulos, Dimitrios M. Tousoulis, Sotirios Tsiodras, Αnastasia Kotanidou, Nikolaos V. Sipsas, Γεώργιος Γιαννόπουλος, Dimitrios A. Vrachatis, Sotiria G. Giotaki, Christos Angelidis, George N. Hahalis, Theofilos M. Kolettis, Haralampos J. Milionis, Panagiotis Gargalianos, S. Baltagiannis, Periklis Panagopoulos, Konstantinos Dolianitis, Efthalia Randou, Nikolaos G. Koulouris, Charalampos Gogos, George D. Tsoukalas, Christoforos D. Olympios, Eleftheria P. Tsagalou, Styliani Gerakari, Ioannis E. Kanonidis, Konstantinos P. Toutouzas, Emmanouil Vavouranakis, on behalf of the GRECCO-19 investigators
2020-06-24

COVID-19cardiac biomarkerscolchicineinflammatory biomarkersrandomized clinical trial
Importance: Severe acute respiratory syndrome coronavirus 2 infection has evolved into a global pandemic. Low-dose colchicine combines anti-inflammatory action with a favorable safety profile. Objective: To evaluate the effect of treatment with colchicine on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019 (COVID-19). Design, Setting, and Participants: In this prospective, open-label, randomized clinical trial (the Greek Study in the Effects of Colchicine in COVID-19 Complications Prevention), 105 patients hospitalized with COVID-19 were randomized in a 1:1 allocation from April 3 to April 27, 2020, to either standard medical treatment or colchicine with standard medical treatment. The study took place in 16 tertiary hospitals in Greece. Intervention: Colchicine administration (1.5-mg loading dose followed by 0.5 mg after 60 min and maintenance doses of 0.5 mg twice daily) with standard medical treatment for as long as 3 weeks. Main Outcomes and Measures: Primary end points were (1) maximum high-sensitivity cardiac troponin level; (2) time for C-reactive protein to reach more than 3 times the upper reference limit; and (3) time to deterioration by 2 points on a 7-grade clinical status scale, ranging from able to resume normal activities to death. Secondary end points were (1) the percentage of participants requiring mechanical ventilation, (2) all-cause mortality, and (3) number, type, severity, and seriousness of adverse events. The primary efficacy analysis was performed on an intention-to-treat basis. Results: A total of 105 patients were evaluated (61 [58.1%] men; median [interquartile range] age, 64 [54-76] years) with 50 (47.6%) randomized to the control group and 55 (52.4%) to the colchicine group. Median (interquartile range) peak high-sensitivity cardiac troponin values were 0.0112 (0.0043-0.0093) ng/mL in the control group and 0.008 (0.004-0.0135) ng/mL in the colchicine group (P = .34). Median (interquartile range) maximum C-reactive protein levels were 4.5 (1.4-8.9) mg/dL vs 3.1 (0.8-9.8) mg/dL (P = .73), respectively. The clinical primary end point rate was 14.0% in the control group (7 of 50 patients) and 1.8% in the colchicine group (1 of 55 patients) (odds ratio, 0.11; 95% CI, 0.01-0.96; P = .02). Mean (SD) event-free survival time was 18.6 (0.83) days the in the control group vs 20.7 (0.31) in the colchicine group (log rank P = .03). Adverse events were similar in the 2 groups, except for diarrhea, which was more frequent with colchicine group than the control group (25 patients [45.5%] vs 9 patients [18.0%]; P = .003). Conclusions and Relevance: In this randomized clinical trial, participants who received colchicine had statistically significantly improved time to clinical deterioration. There were no significant differences in high-sensitivity cardiac troponin or C-reactive protein levels. These findings should be interpreted with caution. Trial Registration: ClinicalTrials.gov Identifier: NCT04326790.
1
In a randomized trial of 105 hospitalized COVID-19 patients, colchicine did not significantly reduce peak high-sensitivity cardiac troponin compared with standard care (P = .34).
2
Patients received colchicine alongside standard treatment, using a 1.5-mg loading dose, an additional 0.5 mg after 60 minutes, and 0.5 mg twice daily for up to 3 weeks.
3
The abstract reports evaluation of colchicine’s effects on inflammatory response, clinical deterioration, mechanical ventilation, mortality, and adverse events in hospitalized COVID-19 patients.
4
The trial was prospective, open-label, randomized, and conducted across 16 tertiary hospitals in Greece between April 3 and April 27, 2020.

Hospitalized patients with coronavirus disease 2019 (COVID-19)

The effects of low-dose colchicine, compared with standard care, on cardiac and inflammatory biomarkers, clinical deterioration, mechanical ventilation, mortality, and adverse events

Publication Details
Publication Date
2020-06-24
Journal
Publisher
ISSN
Cited by
394
Access Type
Author Information
Authors
Christodoulos Stefanadis
Konstantinos P Tsioufis
John A. Goudevenos
Periklis A. Davlouros
Roxana Mehran
Konstantinos Syrigos
Demosthenes G. Katritsis
George Dangas
Vlasios N. Pyrgakis
Giulio Giuseppe Stefanini
Lampros K. Michalis
Bernhard Reimers
Georgios Sianos
Symeon Metallidis
Spyridon G. Deftereos
Antonis S. Manolis
Efstathios K. Iliodromitis
Filippos K. Triposkiadis
Ilias N. Migdalis
Gerasimos Siasos
MICHAEL W. CLEMAN
Katerina Κ. Naka
Luis Martínez‐Dolz
Dimitrios K. Alexopoulos
Dimitrios M. Tousoulis
Sotirios Tsiodras
Αnastasia Kotanidou
Nikolaos V. Sipsas
Γεώργιος Γιαννόπουλος
Dimitrios A. Vrachatis
Sotiria G. Giotaki
Christos Angelidis
George N. Hahalis
Theofilos M. Kolettis
Haralampos J. Milionis
Panagiotis Gargalianos
S. Baltagiannis
Periklis Panagopoulos
Konstantinos Dolianitis
Efthalia Randou
Nikolaos G. Koulouris
Charalampos Gogos
George D. Tsoukalas
Christoforos D. Olympios
Eleftheria P. Tsagalou
Styliani Gerakari
Ioannis E. Kanonidis
Konstantinos P. Toutouzas
Emmanouil Vavouranakis
on behalf of the GRECCO-19 investigators
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%